Sei Investments Co. Has $4.26 Million Holdings in Takeda Pharmaceutical Co. $TAK

Sei Investments Co. increased its holdings in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 20.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 229,943 shares of the company’s stock after acquiring an additional 38,740 shares during the quarter. Sei Investments Co.’s holdings in Takeda Pharmaceutical were worth $4,259,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of TAK. Royal Bank of Canada grew its position in shares of Takeda Pharmaceutical by 11.0% during the 1st quarter. Royal Bank of Canada now owns 441,054 shares of the company’s stock worth $6,558,000 after purchasing an additional 43,706 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Takeda Pharmaceutical by 43.6% during the first quarter. AQR Capital Management LLC now owns 195,740 shares of the company’s stock worth $2,911,000 after purchasing an additional 59,442 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Takeda Pharmaceutical by 15.0% in the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after buying an additional 692,404 shares in the last quarter. Focus Partners Wealth raised its position in shares of Takeda Pharmaceutical by 4.1% in the first quarter. Focus Partners Wealth now owns 82,738 shares of the company’s stock valued at $1,230,000 after buying an additional 3,239 shares in the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in shares of Takeda Pharmaceutical in the second quarter valued at approximately $351,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

TAK stock opened at $16.72 on Thursday. The company’s 50-day moving average price is $16.30 and its two-hundred day moving average price is $17.09. The firm has a market cap of $53.57 billion, a P/E ratio of 49.17 and a beta of -0.08. The company has a quick ratio of 0.60, a current ratio of 1.14 and a debt-to-equity ratio of 0.58. Takeda Pharmaceutical Co. has a 12 month low of $12.99 and a 12 month high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The company had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. On average, analysts anticipate that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Sanford C. Bernstein raised Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Finally, Zacks Research lowered Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Two analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, Takeda Pharmaceutical has an average rating of “Hold”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.